Jeffrey R. Moore - 11 Jul 2023 Form 4 Insider Report for Evelo Biosciences, Inc.

Role
Director
Signature
/s/ Marella Thorell, Attorney-in-Fact for Jeffrey R. Moore
Issuer symbol
EVLO on OTC
Transactions as of
11 Jul 2023
Net transactions value
$0
Form type
4
Filing time
12 Jul 2023, 16:05:55 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Stock Option (Right to Buy) Award $0 +2,000 $0.000000 2,000 11 Jul 2023 Common Stock 2,000 $3.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in 36 substantially equal monthly installments following the grant date and has a term of 10 years.

Remarks:

On June 29, 2023, the Issuer effected a 1-for-20 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.